STOCK TITAN

Viridian Therapeutics (VRDN) Stock News

VRDN NASDAQ

Viridian Therapeutics, Inc. develops antibody-based medicines for autoimmune and rare diseases, with a central focus on thyroid eye disease. Its TED portfolio includes veligrotug, an intravenously administered humanized monoclonal antibody targeting IGF-1R, and elegrobart, a subcutaneously delivered, half-life-extended monoclonal antibody targeting IGF-1R.

Recurring company news covers clinical results from the THRIVE and REVEAL programs, regulatory updates for biologics applications, commercial preparation for TED therapies, and progress across earlier pipeline work, including anti-TSHR and FcRn inhibitor programs. Viridian also reports financial results, public equity and convertible-note financings, royalty-related funding updates, and Nasdaq inducement equity grants tied to employee compensation.

Rhea-AI Summary

Viridian Therapeutics (VRDN) reported phase 1 results for VRDN-008 showing a peak 74% reduction in IgG antibodies in healthy volunteers. Participants received two subcutaneous doses, at study start and week 4. IgG reduction persisted through 8 weeks after dosing. The drug's half-life, the time for its concentration to fall by half, was 15–18 days, up to 6x longer than first-generation Fc fragments. Treatment was generally well tolerated, spared albumin and LDL, and produced no serious adverse events or dose-limiting toxicities.

Viridian believes the results support potential dosing every 8 weeks. It plans at least one registrational trial in 2027, starting with myasthenia gravis in mid-2027, pending regulatory feedback. The planned placebo-controlled trial would test dosing every 4 and 8 weeks. Viridian also plans development in multiple other autoantibody-mediated autoimmune diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.97%
Tags
-
Rhea-AI Summary

Viridian Therapeutics (VRDN) will host a conference call on November 9, 2026, to present VRDN-008 phase 1 clinical trial data. The call and webcast, scheduled for 8:00 a.m. ET, will cover the trial in healthy volunteers and development plans for its neonatal Fc receptor (FcRn) portfolio. A webcast replay will be available on the company website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.97%
Tags
conferences clinical trial
-
Rhea-AI Summary

Viridian Therapeutics (Nasdaq: VRDN) reported $24.7 million in Lumvoa net product revenue during its first launch quarter, ended September 30, 2026. More than 100 patients were on therapy at quarter-end. Total revenue fell to $25.752 million from $70.570 million a year earlier, while net loss widened to $101.209 million from $34.599 million. Research spending declined, but selling, general and administrative expenses increased.

Cash, cash equivalents and marketable securities reached $955.206 million. Viridian expects existing cash and anticipated commercial revenues to fund current plans through profitability, including elegrobart revenue if approved. The company targets an elegrobart application for FDA approval in Q1 2027, VRDN-008 phase 1 data and portfolio development plans in Q4 2026, and initiation of a VRDN-292 phase 1 trial in Graves’ disease patients in Q4 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.53%
Tags
Rhea-AI Summary

Viridian Therapeutics (VRDN) will report third quarter 2026 financial results before the market opens on November 4, 2026. Management will host a live conference call that day at 8:00 a.m. ET to discuss the results and provide a business update. The webcast and an archived replay will be available in the Investors section of the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
earnings date
-
Rhea-AI Summary

Viridian Therapeutics (VRDN) will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 12:45pm ET.

The live webcast will be available via the Investors “Events and Presentations” section of viridiantherapeutics.com, with a replay provided after the event. The company develops therapies for autoimmune and rare diseases, including Lumvoa, an FDA‑approved IGF‑1R antagonist for thyroid eye disease, and elegrobart, a late‑stage investigational subcutaneous TED therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
-
Rhea-AI Summary

Viridian Therapeutics (Nasdaq: VRDN) reported Q2 2026 results and major pipeline and commercial progress. The FDA approved Lumvoa for thyroid eye disease (TED) on June 26, 2026, ahead of its target date, and Viridian immediately launched the drug in the U.S.

By July 31, the company’s field team had engaged 95% of 2,000 core prescribing physicians, with payer coverage efforts on track and first Lumvoa doses administered in July. Viridian is preparing a Q1 2027 BLA submission for elegrobart after positive phase 3 REVEAL-1 and REVEAL-2 results in active and chronic TED. IND submission for its TSHR antibody is planned for Q4 2026, and phase 1 data for FcRn inhibitor VRDN-008 remain on track for 2H 2026.

Cash, cash equivalents, and marketable securities were $981.5 million at June 30, 2026, supported by $394 million of May 2026 financing. Q2 2026 revenue was $0.3 million and net loss was $127.1 million, with lower R&D and higher SG&A as Viridian scales commercial operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.83%
Tags
Rhea-AI Summary

Viridian Therapeutics (Nasdaq: VRDN) received U.S. FDA approval for Lumvoa (veligrotug-vvze) to treat thyroid eye disease (TED) regardless of disease activity or duration and plans an immediate U.S. launch.

Approval followed Priority Review and two pivotal phase 3 THRIVE trials covering both active and chronic TED.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.97%
Tags
-
Rhea-AI Summary

Viridian Therapeutics (Nasdaq: VRDN) will participate in two June 2026 investor conferences. Management will host fireside chats at the Jefferies Global Healthcare Conference on June 3, 2026, at 5:30pm ET in New York and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 4:00pm ET in Miami. Live webcasts and replays will be available in the Investors section of Viridian’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
none
-
Rhea-AI Summary

Viridian Therapeutics (Nasdaq: VRDN) priced upsized concurrent offerings: $225.0 million aggregate principal of 1.75% convertible senior notes due 2032 and 7,352,942 shares of common stock at $17.00 per share, for aggregate gross proceeds of $350.0 million.

Viridian estimates aggregate net proceeds of approximately $334.7 million. Offerings are expected to close on May 11, 2026. Net proceeds will repay Hercules loan, fund TED market expansion studies, advance early pipeline R&D, and for working capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
Rhea-AI Summary

Viridian Therapeutics (Nasdaq: VRDN) announced proposed concurrent public offerings of $150.0 million aggregate principal amount of convertible senior notes due 2032 and $100.0 million of equity (common stock and Series B non-voting convertible preferred stock) on May 5, 2026. Each Series B share converts into 66.67 common shares subject to ownership limits. The offerings include 30-day 15% overallotment options for underwriters. Proceeds are intended to repay outstanding indebtedness to Hercules Capital, fund TED market expansion studies, advance earlier pipeline R&D, and for working capital. Pricing and final terms remain subject to market conditions and SEC prospectus filings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.51%
Tags

FAQ

What is the current stock price of Viridian Therapeutics (VRDN)?

Viridian Therapeutics (VRDN) last closed at $30.87.

What is the market cap of Viridian Therapeutics (VRDN)?

The market cap of Viridian Therapeutics (VRDN) is approximately $3.5B.